Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.

Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I, Bruckmueller H.

Oncotarget. 2017 Sep 26;8(54):92018-92031. doi: 10.18632/oncotarget.21272. eCollection 2017 Nov 3.

2.

Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.

Bruckmueller H, Martin P, Kähler M, Haenisch S, Ostrowski M, Drozdzik M, Siegmund W, Cascorbi I, Oswald S.

Mol Pharm. 2017 Jul 3;14(7):2245-2253. doi: 10.1021/acs.molpharmaceut.7b00076. Epub 2017 Jun 2.

PMID:
28510455
3.

miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model.

Haenisch S, von Rüden EL, Wahmkow H, Rettenbeck ML, Michler C, Russmann V, Bruckmueller H, Waetzig V, Cascorbi I, Potschka H.

ACS Chem Neurosci. 2016 Nov 16;7(11):1585-1594. Epub 2016 Sep 22.

PMID:
27609046
4.

Biodistribution and pharmacokinetics of the (99m)Tc labeled human elastase inhibitor, elafin, in rats.

Kaschwich M, Lützen U, Zhao Y, Tjiong A, Marx M, Haenisch S, Wiedow O, Preuss S, Culman J, Zuhayra M.

Drug Metab Pharmacokinet. 2016 Apr;31(2):146-55. doi: 10.1016/j.dmpk.2016.01.004. Epub 2016 Feb 5.

PMID:
26948953
5.

Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance.

Bruhn O, Drerup K, Kaehler M, Haenisch S, Röder C, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):327-40. doi: 10.2217/pgs.15.175. Epub 2016 Feb 19.

PMID:
26895184
6.

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Schirmer JH, Bremer JP, Moosig F, Holle JU, Lamprecht P, Wieczorek S, Haenisch S, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):367-74. doi: 10.2217/pgs.15.176. Epub 2016 Feb 19.

PMID:
26894931
7.

SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.

Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL.

Neurobiol Dis. 2015 May;77:127-40. doi: 10.1016/j.nbd.2015.02.025. Epub 2015 Mar 10.

8.

Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.

Werk AN, Bruckmueller H, Haenisch S, Cascorbi I.

Pharmacogenet Genomics. 2014 Jun;24(6):283-91. doi: 10.1097/FPC.0000000000000046.

PMID:
24743544
9.

MicroRNAs and their relevance to ABC transporters.

Haenisch S, Werk AN, Cascorbi I.

Br J Clin Pharmacol. 2014 Apr;77(4):587-96. doi: 10.1111/bcp.12251. Review.

10.

Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease.

Cascorbi I, Flüh C, Remmler C, Haenisch S, Faltraco F, Grumbt M, Peters M, Brenn A, Thal DR, Warzok RW, Vogelgesang S.

Pharmacogenomics. 2013 Apr;14(5):485-94. doi: 10.2217/pgs.13.18.

PMID:
23556446
11.

miRNAs as mediators of drug resistance.

Haenisch S, Cascorbi I.

Epigenomics. 2012 Aug;4(4):369-81. doi: 10.2217/epi.12.39. Review.

PMID:
22920178
12.

MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.

Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I.

Pharmacogenet Genomics. 2012 Mar;22(3):198-205. doi: 10.1097/FPC.0b013e328350012b.

PMID:
22241070
13.

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I.

Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.

PMID:
22012257
14.

Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.

Ufer M, von Stülpnagel C, Muhle H, Haenisch S, Remmler C, Majed A, Plischke H, Stephani U, Kluger G, Cascorbi I.

Pharmacogenet Genomics. 2011 Oct;21(10):624-30. doi: 10.1097/FPC.0b013e3283498131.

PMID:
21799461
15.

Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379.

Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, Remmler C, Cascorbi I.

Mol Pharmacol. 2011 Aug;80(2):314-20. doi: 10.1124/mol.110.070714. Epub 2011 May 3.

16.

Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients.

Binder A, May D, Baron R, Maier C, Tölle TR, Treede RD, Berthele A, Faltraco F, Flor H, Gierthmühlen J, Haenisch S, Huge V, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Uçeyler N, Ufer M, Wasner G, Zhu J, Cascorbi I.

PLoS One. 2011 Mar 29;6(3):e17387. doi: 10.1371/journal.pone.0017387.

17.

Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method.

Staab CA, Stegk JP, Haenisch S, Neiss E, Köbsch K, Ebert B, Cascorbi I, Maser E.

Chem Biol Interact. 2011 May 30;191(1-3):104-12. doi: 10.1016/j.cbi.2010.12.027. Epub 2011 Jan 6.

PMID:
21215738
18.

Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.

Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S.

Pharmacogenomics J. 2011 Feb;11(1):25-34. doi: 10.1038/tpj.2010.20. Epub 2010 Mar 30.

PMID:
20351751
19.

Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.

Afsar NA, Haenisch S, Mateen A, Usman A, Ufer M, Ahmed KZ, Ahmad HR, Cascorbi I.

Basic Clin Pharmacol Toxicol. 2010 Jul;107(1):570-6. doi: 10.1111/j.1742-7843.2009.00531.x. Epub 2010 Jan 19.

20.

Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity.

Ufer M, Häsler R, Jacobs G, Haenisch S, Lächelt S, Faltraco F, Sina C, Rosenstiel P, Nikolaus S, Schreiber S, Cascorbi I.

Pharmacogenomics. 2009 Dec;10(12):1941-53. doi: 10.2217/pgs.09.128.

PMID:
19958093
21.

Pharmacogenetics of ATP-binding cassette transporters and clinical implications.

Cascorbi I, Haenisch S.

Methods Mol Biol. 2010;596:95-121. doi: 10.1007/978-1-60761-416-6_6.

PMID:
19949922
22.

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.

Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Häsler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I.

Pharmacogenet Genomics. 2009 May;19(5):353-62.

PMID:
19415824
23.

Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.

Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W.

Pharmacogenet Genomics. 2008 Apr;18(4):357-65. doi: 10.1097/FPC.0b013e3282f974b7.

PMID:
18334920
24.

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.

Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I.

Clin Pharmacol Ther. 2007 Feb;81(2):228-34. Epub 2006 Dec 27.

PMID:
17192769
25.

Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.

Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I.

Pharmacogenomics J. 2007 Feb;7(1):56-65. Epub 2006 Jun 20. Erratum in: Pharmacogenomics J. 2007 Feb;7(1):74. Siegmund, S [corrected to Siegmund, W].

PMID:
16788565
26.

Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, Haenisch S, Cascorbi I, Terhaag B, Siegmund W.

Br J Clin Pharmacol. 2006 Apr;61(4):440-50.

27.

Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.

Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W.

Clin Pharmacol Ther. 2006 Mar;79(3):206-17. Epub 2006 Feb 7.

PMID:
16513445
28.

Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation.

Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK.

Drug Metab Dispos. 2005 Jul;33(7):896-904. Epub 2005 Apr 8.

Supplemental Content

Loading ...
Support Center